Lebrikizumab Provides Stable and Deep Long-Term Response with No/Minimal Fluctuations up to 3 Years in Patients with Moderate-to-Severe Atopic Dermatitis. (PubMed, Dermatol Ther (Heidelb)) - Oct 23, 2026 - P3 | "Continuous lebrikizumab treatment through 3 years provided stable disease control in skin and itch symptoms, with infrequent flares experienced by week 16 responders with moderate-to-severe AD."
Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus
|
|
Andreas Wollenberg; Chao Yang; Christian Vestergaard; Eric Wolf; Gaia Gallo; H Chih-Ho Hong; Helena Agell; James Del Rosso; José Manuel Carrascosa; Joseph Merola; Ken Igawa; Leon Kircik; Linda Stein Gold; Peter Lio; Yuxin Ding
|